ProShare Advisors LLC Makes New $373,000 Investment in BeOne Medicines Ltd. – Sponsored ADR $ONC

ProShare Advisors LLC purchased a new stake in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,542 shares of the company’s stock, valued at approximately $373,000.

Several other institutional investors have also modified their holdings of ONC. Caitong International Asset Management Co. Ltd bought a new stake in BeOne Medicines in the 2nd quarter valued at about $28,000. Farther Finance Advisors LLC bought a new position in BeOne Medicines in the 2nd quarter worth about $39,000. Signaturefd LLC bought a new position in BeOne Medicines in the 2nd quarter worth about $49,000. Parallel Advisors LLC acquired a new stake in shares of BeOne Medicines in the second quarter valued at approximately $59,000. Finally, FNY Investment Advisers LLC bought a new stake in shares of BeOne Medicines during the second quarter valued at approximately $121,000. Institutional investors own 48.55% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on ONC shares. Jefferies Financial Group reiterated a “buy” rating and set a $420.00 price objective on shares of BeOne Medicines in a research report on Monday. Citizens Jmp boosted their price target on BeOne Medicines from $348.00 to $396.00 and gave the stock a “market outperform” rating in a research report on Friday, November 7th. Guggenheim raised their price target on BeOne Medicines from $350.00 to $365.00 and gave the company a “buy” rating in a report on Thursday, August 7th. Zacks Research cut shares of BeOne Medicines from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 28th. Finally, Barclays started coverage on shares of BeOne Medicines in a research report on Thursday, September 18th. They issued an “overweight” rating and a $385.00 target price for the company. Eleven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, BeOne Medicines currently has a consensus rating of “Moderate Buy” and an average price target of $363.15.

Insider Activity

In other news, COO Xiaobin Wu sold 10,000 shares of BeOne Medicines stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $356.02, for a total value of $3,560,200.00. Following the transaction, the chief operating officer owned 6,009 shares of the company’s stock, valued at $2,139,324.18. The trade was a 62.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Corazon (Corsee) D. Sanders sold 2,665 shares of the business’s stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $337.00, for a total transaction of $898,105.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 81,254 shares of company stock valued at $27,971,587 over the last quarter. Insiders own 6.62% of the company’s stock.

BeOne Medicines Stock Down 1.3%

ONC opened at $349.29 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.17 and a current ratio of 2.39. The company has a market capitalization of $41.40 billion, a PE ratio of 684.88 and a beta of 0.31. The stock’s fifty day moving average is $331.83 and its 200-day moving average is $294.40. BeOne Medicines Ltd. – Sponsored ADR has a one year low of $170.99 and a one year high of $385.22.

BeOne Medicines Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.